Search Results

2 items found for "talquetamab"

Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma
< GPCR News < GPCRs in Oncology and Immunology Structural Basis for the Recognition of GPRC5D by Talquetamab Talquetamab, a Food and Drug Administration-approved T-cell-directing bispecific antibody developed for Here, we elucidate the structure of GPRC5D complexed with the Fab fragment of talquetamab, using cryo-electron A single talquetamab Fab interacts with the GPRC5D dimer with its orientation toward the dimer interface All six complementarity-determining regions of talquetamab engage with extracellular loops and TM3/5/
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
strategies in an international cohort of 139 patients (n = 130 ide-cel, n = 9 cilta-cel), receiving talquetamab Overall response and complete response upon salvage therapies were 79% and 39% for talquetamab, 64% and